Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the class of organic compounds known as 2-phenylindoles. It features an indole core substituted at the 2-position with a methyl-substituted phenyl group and a carboximidamide functional group at the 6-position[1][5][6]. This compound has been studied primarily in experimental settings for its antiproliferative (anticancer) and neuroprotective properties. Mechanistically, it induces apoptosis in cancer cells via caspase activation and modulates apoptotic markers such as Cytochrome C and Bcl-2 family proteins. It also inhibits kinases like EGFR and CDK2, contributing to its anticancer effects[5]. Preliminary research suggests potential applications in neurodegenerative diseases such as Alzheimer's disease by targeting neuronal apoptosis pathways[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(2-methylphenyl)-1H-indole-6-carboximidamide.